Oral @entity2134 to treat vaginal xerosis associated with chemotherapy-induced @entity2588 in pre-menopausal XXXX .

@entity172 @entity1 @entity5 @entity2133 @entity786 @entity2134 @entity244 @entity2588
UNASSIGNED: 8099 Background: Chemotherapy-induced @entity2588 frequently results in side effects common to those experienced in menopause; @entity2133 ( @entity2133 ) and its related symptoms are prominent examples. Although many of these side effects respond to the use of @entity172 replacement therapy (ERT), many @entity5 survivors choose to not chance the risks linked with ERT. Previous results in a placebo-controlled Phase III study treating xeroses associated with @entity244 with oral @entity2134 (OP){Salagen   Tablets}demonstrated impressive improvement in @entity2133 , P<= 0.02 (25% vs.14%):Vivino et al; Arch Intern Med. 1999;159. METHODS: A 12-week, open-label pilot study was conducted using OP (5mg./qid) in pre-menopausal @entity1 with @entity2133 caused by the effects of high cumulative dose @entity786 on ovarian function. Study enrollment required a minimum 2 month history of @entity2133 and 4 months status-post chemotherapy. The primary endpoint of this study was a global assessment of @entity2133 measured on a standard visual analog scale (VAS), at 6 and 12 weeks of treatment, or at final study visit if prior to week 12. @entity1 were asked to characterize their @entity2133 at these visits compared to their @entity2133 before treatment with OP; each @entity1 acted as her own control. RESULTS: The pre-study expectation was for a 25 mm (absolute) improvement in the @entity1 ' VAS by end of study. Four of four evaluable @entity1 treated with OP experienced a marked clinical improvement in @entity2133 .Three responders recorded >= 40mm absolute gain in VAS, the fourth gained >= 28mm. CONCLUSIONS: OP, a well-tolerated muscarinic agonist was able to stimulate remaining mucus and other moisture producing cells in the vaginal mucosa _ muscularis to the extent that a marked clinical improvement in @entity2133 was experienced by each of the study @entity1 . The only AEs experienced were mild and of the known side effects of OP and did not interfere with treatment. These results warrant further investigation as a possible treatment for symptomatic relief of this difficult problem. No significant financial relationships to disclose.
